Pillar · Biotech Investing
Biotech Due Diligence Checklist: How to Evaluate a Drug Pipeline and Probability of Approval
Most biotech investors skip due diligence and pay the price. This step-by-step checklist walks you through everything yo...
Start here
Pillar · Clinical Readouts
How to Read Biotech Clinical Trial Data: Phase 1, 2, 3 Results Explained for Investors
Clinical trial data is the single most important factor in biotech investing, but most investors struggle to read it. Th...
Therapeutic Areas
The Most Crowded Drug Targets in Biotech: 19 Companies Are Chasing CD19
19 biotechs are chasing CD19 and the median is worth $600M. 547 of 675 molecular targets have just one company on them....
FDA & PDUFA Calendar
IGALMI PDUFA and Namodenoson Data: Catalysts Sep 7
On November 14, 2026, IGALMI's approval decision could reshape agitation treatment in psychiatry. Explore pivotal biotech catalysts to watch....
Therapeutic Areas
Biotech Companies by Disease: $672B Across 299 Indications, 198 Uncontested
198 of 299 diseases have exactly one US-listed biotech developing a drug for them. The crowded ones carry the cheapest companies....
FDA & PDUFA Calendar
FDA Calendar: Upcoming PDUFA Dates and Drug Approval Decisions
As we enter Q3 2026, several pivotal FDA decisions are on the horizon, including BTAI's IGALMI with a November 14 PDUFA date....
FDA & PDUFA Calendar
Biotech Penny Stock Catalysts: FDA and PDUFA Dates 2026
On November 14, 2026, BioXcel Therapeutics could see a pivotal moment with IGALMI, a drug for bipolar agitation. Is it time to invest?...
FDA & PDUFA Calendar
FDA Calendar September 2026: A Critical Look at Upcoming Approvals
September 2026 brings significant PDUFA dates, including Zidesamtinib and Ameluz®PDT. Here's what investors need to know....
FDA & PDUFA Calendar
Gossamer Seralutinib in PAH: Catalysts Aug 31 2026
GOSS's seralutinib (GB002) targets PAH with a 58% approval probability. Explore catalysts including PDUFA dates and market implications for 2026....
Catalyst Analysis
Biotech Stocks Hedge Funds Are Buying: $127.3B Across 520 Names, Q2 2026
44 biotech specialist funds hold a record $127.3B across 520 companies, the fewest ever. One ownership signal clears significance, and it is a negative one....
FDA & PDUFA Calendar
SION-451 Cystic Fibrosis Risk: Catalysts Aug 24
As of August 24, 2026, several biotech catalysts are set to shape the market landscape, with key dates approaching for critical drug approvals....